EA200971062A1 - Производные ариламидпиримидона - Google Patents

Производные ариламидпиримидона

Info

Publication number
EA200971062A1
EA200971062A1 EA200971062A EA200971062A EA200971062A1 EA 200971062 A1 EA200971062 A1 EA 200971062A1 EA 200971062 A EA200971062 A EA 200971062A EA 200971062 A EA200971062 A EA 200971062A EA 200971062 A1 EA200971062 A1 EA 200971062A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
alkyl group
atom
hydrogen atom
optionally substituted
Prior art date
Application number
EA200971062A
Other languages
English (en)
Inventor
Натали Шерез
Тьерри Галле
Алистер Локхед
Мурад Саади
Коринн Вероник
Филипп Иэш
Original Assignee
Санофи-Авентис
Мицубиси Танабе Фарма Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис, Мицубиси Танабе Фарма Корпорейшн filed Critical Санофи-Авентис
Publication of EA200971062A1 publication Critical patent/EA200971062A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

Производное пиримидона, представленное формулой (I) или его соли, сольваты или гидраты, в которой Х представляет собой два атома водорода, атом серы, атом кислорода или Cалкильную группу и атом водорода; Z представляет собой связь, атом кислорода, атом азота, замещенный атомом водорода или Cалкильной группой, атом серы, метиленовую группу, необязательно замещенную одной или двумя группами, выбранными из Cалкильной группы, гидроксильной группы, Cалкоксигруппы, Cпергалогенированной алкильной группы или аминогруппы; R1 представляет собой 2-, 4- или 5-пиримидиновое кольцо или 4-пиридиновое кольцо, которое является необязательно замещенным Cалкильной группой, Cалкоксигруппой или атомом галогена; R2 представляет собой бензольное кольцо, нафталиновое кольцо или бензильную группу; причем эти кольца необязательно замещены 1-4 заместителями, выбранными из Cалкильной группы, Сциклоалкильной группы, Сциклоалкил-Салкильной группы, атома галогена, Cпергалогенированной алкильной группы, Cгалогенированной алкильной группы, гидроксильной группы, гетероарильной группы, необязательно замещенной Cалкильной группой, Сциклоалкильной группой, Сциклоалкил-Салкильной группой, Cалкоксигруппой, необязательно замещенной Сциклоалкильной группой, Cпергалогенированной алкоксигруппой, Cалкилсульфонильной группой, нитро, циано, амино, Cмоноалкиламино группой или Cдиалкиламино группой, ацетокси группы или аминосульфонильной группы; R3 представляет собой атом водорода, Cалкильную группу или атом галогена; R4 представляет собой атом водорода или Cалкильную группу; R5 представляет собой атом водорода или Cалкильную группу; R6 представляет собой атом водорода или Cалкильную группу; R7 представляет собой атом водорода или Cалкильную группу; n представляет собой 0-3 и m представляет собой 0, в форме свободного основания или соли присоединения кислоты.
EA200971062A 2007-05-16 2008-05-14 Производные ариламидпиримидона EA200971062A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290625A EP1992620A1 (en) 2007-05-16 2007-05-16 Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
PCT/IB2008/002446 WO2008155669A2 (en) 2007-05-16 2008-05-14 Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
EA200971062A1 true EA200971062A1 (ru) 2010-06-30

Family

ID=38610549

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200971062A EA200971062A1 (ru) 2007-05-16 2008-05-14 Производные ариламидпиримидона

Country Status (15)

Country Link
US (1) US8592436B2 (ru)
EP (2) EP1992620A1 (ru)
JP (1) JP5509070B2 (ru)
KR (1) KR20100016528A (ru)
CN (1) CN101679305A (ru)
AR (1) AR066603A1 (ru)
AU (1) AU2008264901A1 (ru)
BR (1) BRPI0811527A2 (ru)
CA (1) CA2687258A1 (ru)
EA (1) EA200971062A1 (ru)
IL (1) IL201562A0 (ru)
MX (1) MX2009012383A (ru)
NZ (1) NZ581163A (ru)
TW (1) TW200904436A (ru)
WO (1) WO2008155669A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2406233B1 (en) * 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145423A (en) 1976-02-10 1979-03-20 Rhone-Poulenc Industries Pyrimidinyl-1,2-dithiole compounds and anti-bilharzia compositions thereof
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
JP4533534B2 (ja) * 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
GB9820658D0 (en) 1998-09-22 1998-11-18 Medical Res Council Treatment of infection
EP1430056B1 (en) 2001-09-21 2005-10-26 Sanofi-Aventis Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
US7683069B2 (en) 2002-12-16 2010-03-23 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
EP1454909B1 (en) * 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
CA2516934C (en) 2003-03-07 2011-09-20 Sanofi-Aventis Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
EP1790649A1 (en) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives

Also Published As

Publication number Publication date
JP5509070B2 (ja) 2014-06-04
NZ581163A (en) 2011-09-30
EP1992620A1 (en) 2008-11-19
TW200904436A (en) 2009-02-01
WO2008155669A3 (en) 2009-06-04
BRPI0811527A2 (pt) 2014-11-18
IL201562A0 (en) 2010-05-31
AR066603A1 (es) 2009-09-02
KR20100016528A (ko) 2010-02-12
WO2008155669A2 (en) 2008-12-24
JP2010526866A (ja) 2010-08-05
CN101679305A (zh) 2010-03-24
AU2008264901A1 (en) 2008-12-24
EP2148866B1 (en) 2013-07-17
MX2009012383A (es) 2009-12-03
CA2687258A1 (en) 2008-12-24
US20100087460A1 (en) 2010-04-08
EP2148866A2 (en) 2010-02-03
US8592436B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
EA200971062A1 (ru) Производные ариламидпиримидона
EA200971061A1 (ru) Пиримидоновые соединения гетероариламидов
EA200971063A1 (ru) Ариламидпиримидоновые соединения
EA201070890A1 (ru) Замещенные ариламидные производные оксазепинопиримидона
EA200971060A1 (ru) Гетероариламидные пиримидоновые производные
EA201070891A1 (ru) Замещенные гетероариламидные производные диазепинопиримидона
EA201070889A1 (ru) Замещённые гетероариламидные производные оксазепинопиримидона
HRP20070328T3 (en) SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKLYMINE]-PYRIMIDO[1,2a]PYRIMIDIN-6-ONE DERIVATIVES
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
RS52546B (en) 1H-BENZIMIDAZOL-4-CARBOXAMIDES SUBSTITUTED WITH QUATERNERN CARBON AT POSITION-2 ARE POWERFUL PARP INHIBITORS
RS51654B (en) DERIVATIVES OF THE SUBSTITUTED BICYCLIC PIRIMIDONE
CY1109345T1 (el) ΠΑΡΑΓΩΓΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 8-ΥΠΕΡΦΘΟΡΟΑΛΚΥΛΟ-6,7,8,9-ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ (1,2-a) ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ
EA201170098A1 (ru) Замещенные производные алкилпиримидин-4-она
EA201070896A1 (ru) ЗАМЕЩЕННЫЕ АРИЛАМИДДИАЗЕПИНОПИРИМИДОНОВЫЕ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ АНОМАЛЬНОЙ АКТИВНОСТЬЮ GSK3β
HRP20090151T3 (en) Indozolone derivatives as 11b-hsd1 inhibitors
MEP8409A (en) Fused heterocyclic compound
CY1112006T1 (el) Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
EA201100975A1 (ru) Производные 1,2,4-оксадиазола и их применение в терапии
CY1109890T1 (el) ΠΑΡΑΓΩΓΑ 8-ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ-6,7,8,9- ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ[1,2-α] ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
MX2009006024A (es) Derivados de heteroaril piridopirimidona sustituidos.
EA201170093A1 (ru) Замещенные n-оксидпиразиновые производные
BRPI0510075A (pt) benzoxazocinas e seu uso terapêutico como inibidores de reabsorção de monoamina
ATE500243T1 (de) Carbonsäureamidverbindung und deren verwendung